Foundations Investment Advisors LLC grew its holdings in Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 27.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 63,082 shares of the biopharmaceutical company's stock after purchasing an additional 13,417 shares during the quarter. Foundations Investment Advisors LLC's holdings in Gilead Sciences were worth $5,827,000 at the end of the most recent reporting period.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. nVerses Capital LLC acquired a new position in shares of Gilead Sciences during the third quarter worth $25,000. Valued Wealth Advisors LLC increased its position in Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 161 shares in the last quarter. Decker Retirement Planning Inc. purchased a new stake in Gilead Sciences in the fourth quarter valued at about $29,000. Strategic Investment Solutions Inc. IL acquired a new stake in Gilead Sciences in the second quarter worth about $33,000. Finally, Quarry LP purchased a new stake in shares of Gilead Sciences during the second quarter worth about $43,000. 83.67% of the stock is currently owned by institutional investors.
Gilead Sciences Price Performance
Shares of Gilead Sciences stock traded down $1.50 during trading on Tuesday, hitting $93.85. 7,405,270 shares of the company were exchanged, compared to its average volume of 6,868,622. The firm has a 50 day moving average price of $91.88 and a 200 day moving average price of $85.27. The company has a quick ratio of 1.10, a current ratio of 1.26 and a debt-to-equity ratio of 1.24. The stock has a market capitalization of $116.96 billion, a price-to-earnings ratio of 1,042.78, a P/E/G ratio of 1.31 and a beta of 0.18. Gilead Sciences, Inc. has a fifty-two week low of $62.07 and a fifty-two week high of $98.90.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its earnings results on Wednesday, November 6th. The biopharmaceutical company reported $2.02 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.58 by $0.44. The business had revenue of $7.55 billion for the quarter, compared to analysts' expectations of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The company's quarterly revenue was up 7.0% on a year-over-year basis. During the same period last year, the company earned $2.29 earnings per share. On average, equities analysts expect that Gilead Sciences, Inc. will post 4.36 earnings per share for the current fiscal year.
Gilead Sciences Announces Dividend
The firm also recently announced a quarterly dividend, which was paid on Monday, December 30th. Investors of record on Friday, December 13th were issued a dividend of $0.77 per share. The ex-dividend date of this dividend was Friday, December 13th. This represents a $3.08 annualized dividend and a dividend yield of 3.28%. Gilead Sciences's payout ratio is 3,422.22%.
Analysts Set New Price Targets
Several analysts have weighed in on GILD shares. Citigroup assumed coverage on shares of Gilead Sciences in a research report on Thursday, November 14th. They set a "buy" rating and a $125.00 target price on the stock. Leerink Partnrs raised Gilead Sciences from a "hold" rating to a "strong-buy" rating in a report on Monday, October 21st. JPMorgan Chase & Co. increased their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the stock an "overweight" rating in a report on Thursday, November 7th. Cantor Fitzgerald reiterated a "neutral" rating and issued a $80.00 price objective on shares of Gilead Sciences in a research note on Wednesday, December 11th. Finally, Bank of America restated a "buy" rating and set a $109.00 target price on shares of Gilead Sciences in a research report on Tuesday, December 10th. Eleven equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and four have issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and a consensus price target of $97.96.
Get Our Latest Stock Report on GILD
Insider Transactions at Gilead Sciences
In other news, CFO Andrew D. Dickinson sold 2,500 shares of the company's stock in a transaction dated Wednesday, January 15th. The shares were sold at an average price of $91.35, for a total transaction of $228,375.00. Following the completion of the transaction, the chief financial officer now owns 129,873 shares in the company, valued at approximately $11,863,898.55. This represents a 1.89 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Merdad Parsey sold 25,590 shares of the firm's stock in a transaction that occurred on Wednesday, November 6th. The shares were sold at an average price of $91.50, for a total transaction of $2,341,485.00. Following the completion of the sale, the insider now owns 99,599 shares in the company, valued at $9,113,308.50. The trade was a 20.44 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 456,234 shares of company stock valued at $42,130,461 over the last quarter. Company insiders own 0.16% of the company's stock.
About Gilead Sciences
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
Further Reading
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
